Topiramate plus ASMs vs placebo plus ASMs
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
- no estimate extracted1 study · 98 participantsLow
Findings
What do systematic reviews say?
1,261 questions · 1,287 findings · 210 reviews
No studies found 256 · 19.9%GRADE not reported 123 · 9.6%Very low 248 · 19.3%Low 403 · 31.3%Moderate 208 · 16.2%High 49 · 3.8%
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs vs placebo plus ASMs
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
- RR 6.62 [1.56, 28.15]2 studies · 396 participantsHigh
Cinromide plus ASMs vs placebo plus ASMs
Seizure freedom · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
- no estimate extracted1 study · 56 participantsVery low
Cinromide plus ASMs vs placebo plus ASMs
Number of participants with ≥ 75% reduction in mean weekly seizures · Lennox‐Gastaut syndrome, any age
It is very uncertain whether cinromide plus ASMs changes number of participants with ≥ 75% reduction in mean weekly seizures compared with placebo plus ASMs (very low certainty).
1 finding from 1 review
- Peto OR 9.35 [0.45, 194.96]1 study · 56 participantsVery low
Cinromide plus ASMs vs placebo plus ASMs
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
It is very uncertain whether cinromide plus ASMs changes number of participants with ≥ 50% reduction in mean weekly seizures compared with placebo plus ASMs (very low certainty).
1 finding from 1 review
- RR 1.15 [0.47, 2.86]1 study · 56 participantsVery low
Cinromide plus ASMs vs placebo plus ASMs
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Clobazam (low, medium and high doses) plus ASMs vs placebo plus ASMs
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
CPOE/CDSS vs control/paper‐based
ADEs ( · adults
It is very uncertain whether CPOE/CDSS changes ADEs ( compared with control/paper‐based (very low certainty).
1 finding from 1 review
- OR 0.24 [0.04, 1.5]2 studies · 827 participantsVery low
CPOE/CDSS vs control/paper‐based
Mortality during hospitalisation ( · adults
It is very uncertain whether CPOE/CDSS changes mortality during hospitalisation ( compared with control/paper‐based (very low certainty).
1 finding from 1 review
- RR 1.04 [0.54, 2.01]1 study · 737 participantsVery low
CPOE/CDSS vs control/paper‐based
Length of stay · adults
1 finding from 1 review
- no estimate extracted1 study · 737 participantsVery low
Improved CPOE/CDSS vs standard CPOE/CDSS
ADEs ( · adults
Improved CPOE/CDSS probably leads to lower ADEs ( compared with standard CPOE/CDSS (moderate certainty).
1 finding from 1 review
- OR 0.82 [0.71, 0.94]2382 participantsModerate
CPOE/CDSS: prioritised vs non‐prioritised alerts
Resolved potential ADEs (per prescriptions) ( · adults
1 finding from 1 review
- no estimate extracted1 participantsLow
Modafinil vs placebo
Epworth Sleepiness Scale (ESS), week 3№ of participants: 101(2 RCTs) · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedHigh
Clarithromycin vs placebo
Total nocturnal sleep time (minutes) · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Clarithromycin vs placebo
Difficulty waking in the morning, average of weeks 1 and 2№ of participants: 10(1 RCT) · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Clarithromycin vs placebo
Psychomotor vigilance task (PVT) reciprocal of reaction time, change from baseline№ of participants: 10(1 RCT) · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Clarithromycin vs placebo
Quality of life Functional Outcomes of Sleep Questionnaire · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Clarithromycin vs placebo
Number of participants with any adverse events№ of participants: 10(1 RCT) · idiopathic hypersomnia
Clarithromycin showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyOR 0.41 [0.01, 12.64]Studies not reportedLow
Modafinil vs placebo
Number of naps/week, week 3№ of participants: 99(2 RCTs) · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Modafinil vs placebo
Clinical Global Impression ‐ Severity (CGI‐S), change from baseline№ of participants: 30(1 RCT) · idiopathic hypersomnia
1 finding from 1 review
- Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedModerate